Showing 1 - 2 results of 2 for search 'Yinduo Zeng', query time: 0.02s Refine Results
  1. 1
    Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system

    Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system by Xiujuan Gui, Jianli Zhao, Linxiaoxiao Ding, Jie Chai, Hongna Lai, Yangyang Cai, Simin Luo, Yinduo Zeng, Wenjing Wu, Haizhu Chen, Herui Yao, Ying Wang

    Published 2023-10-01
    Get full text
    Article
  2. 2
    Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

    Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer by Jieqiong Liu, Ying Wang, Zhenluan Tian, Ying Lin, Hengyu Li, Zhaowen Zhu, Qiang Liu, Shicheng Su, Yinduo Zeng, Weijuan Jia, Yaping Yang, Shengqiang Xu, Herui Yao, Wen Jiang, Erwei Song

    Published 2022-05-01
    Get full text
    Article

Search Tools: